It was in 1998 that Clay B. Siegall, Ph.D. co-founded Seattle Genetics, Inc. His roles at the company include Chief Executive Officer, President, and Chairman of the Board. Dr. Siegall is a scientist who specializes in targeted cancer therapies. His leadership has made Seattle Genetics a worldwide leader in developing antibody-drug conjugates (ADCs) and the release of their first ADC cancer drug, Adcetris, which is used to treat lymphoma. Dr. Siegall partnered with Takeda Pharmaceutical Company on Adcetris and it is now approved for use in over 65 countries. There are more than 20 other ADCs that are being researched at Seattle Genetics for their potential in treating other types of cancer.
As the top executive at Seattle Genetics, Dr. Clay Siegall is instrumental in developing strategic partnerships and licensing. He has spearheaded multiple business relationships including those Seattle Genetics has with GlaxoSmithKline, Pfizer, Abbvie, and Roche. He also is in charge of raising capital at the firm and he has successfully used public and private sources to bring in more than $1.2 billion in funding.
Dr. Siegall started his career in cancer research and development. He first worked for the National Cancer Institute from 1988 to 1991. He joined Bristol-Myers Squibb Pharmaceutical Research Institute in Seattle, Washington and stayed with them for six years before founding his own company. As a leader in the research community, he also has a seat on the Board of Directors for other biotechnology companies including Alder BioPharmaceuticals and Ultragenyx Pharmaceutical. His executive leadership was recognized when he was asked to join the Washington Roundtable on their Board of Directors.
Dr. Siegall developed his passion for curing cancer when his father developed the disease when Clay was just 19 years old. His father died when he was 24 and during those five years he saw just how few tools Oncologists had to treat cancer effectively. This passion led him to secure his Doctorate in Genetics at George Washington University.
Even 30 years into his career, Dr. Siegall wakes up energized and ready to get to work. Helping cure cancer is his passion is his daily passion and something that he truly loves to do.